TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
What this study shows
Akt directly phosphorylates and inactivates TSC2, disrupting the TSC1-TSC2 complex and releasing its inhibition of mTOR - the link between growth-factor/insulin signaling and mTORC1 activation.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Human cell lines) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Human cell lines |
| Journal | Nature Cell Biology |
| Year | 2002 |
| Peer reviewed | Yes |
| Record last updated | 2026-08-22 |
| Source | DOI 10.1038/ncb839 · PMID 12172553 |
Extracted findings
| Intervention | Biochemical/genetic (Akt phosphorylation of TSC2) |
| Target | TSC2 / Akt / mTOR |
| Model | Human cell lines |
| Effect | Akt phosphorylates and inactivates TSC2 → relieves mTOR inhibition (links insulin/growth factors to mTORC1) |
In the Atlas
Related topics
More studies on this topic
- The phosphoinositide 3-kinase pathway (2002)
- mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment (2026)
- Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways (2001)
- Decoding the PI3K/Akt/mTOR-JAK/STAT signaling axis in multiple sclerosis: mechanistic crosstalk and therapeutic opportunities. (2026)
Learn the biology
Want to understand the biology behind this study? → Rheb — The Critical Regulator